Biogen (BIIB) Tops Q2 EPS by 59c, Sales Beat; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Biogen (BIIB) PT Raised to $328 at BMO Capital; '2Q17 Couldn’t Have Been Better Operationally'
July 26, 2017 10:53 AM EDTBMO Capital raised its price target on Biogen (NASDAQ: BIIB) to $328.00 (from $317.00) while maintaining a Market Perform rating, following the company's second quarter earnings announcement.
Analyst M. Ian Somaiya notes the company delivered second quarter earnings per share and revenues above consensus... More
Biogen (BIIB) PT Raised to $285 at UBS Following Strong 2Q
July 26, 2017 8:44 AM EDTUBS raised its price target on Biogen (NASDAQ: BIIB) to $285.00 (from $270.00) while maintaining a Neutral rating following the company's 2Q. BIIB recorded a $284M top-line beat. EPS also came in ahead with a $0.53 beat.
Despite a strong 2Q print, the mid-to-long term outlook... More
Biogen (BIIB) PT Raised to $319 at Deutsche Bank
July 26, 2017 6:24 AM EDTDeutsche Bank raised its price target on Biogen (NASDAQ: BIIB) to $319.00 (from $315.00) while maintaining a Buy rating amid solid Q2 results and strategic review.
Analyst Andrew Peters commented, "The outperformance, driven primarily by strength in the MS franchise, as well as by continued... More
